Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Devices, systems and methods for the production of humanized gut commensal microbiota

a technology of gut microbiota and production method, which is applied in the field of ex vivo production of gut microbiota, can solve the problems of obesity, other conditions, and difficulty in understanding the exact mechanism of microbial influence in disease pathogenesis

Inactive Publication Date: 2018-02-01
SUBHADRA BOBBAN
View PDF0 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes a platform for producing human gut microbiota in a way that can be used to treat various conditions in a person. The platform includes a system for culturing the microbiota in a way that mimics the environment of the human gut. The microbiota can be screened and selected from a healthy donor, and then used to treat gastrointestinal illnesses or other conditions by being administered to a person. The technical effects of this patent include a method for producing a personalized gut microbiota with defined characteristics that can be used for therapeutic purposes.

Problems solved by technology

However, the precise mechanism of this microbial influence in disease pathogenesis remains elusive and is now a major research focus.
Other conditions such as obesity are more difficult to comprehend in terms of the mechanisms that might be playing a role in the causality of obesity yet originating in the bowel flora.
In addition, because of undesirable side effects, the Food and Drug Administration (FDA) has had to recall several obesity drugs from the market.
Those that are approved also have side effects.
An unpleasant side effect with orlistat, however, is the passage of undigested oily fat from the body.
In the process, it also causes elevation of blood pressure and an increase in heart rate.
Other appetite suppressants, such as amphetamine derivatives, are highly addictive and have the potential for abuse.
Moreover, different subjects respond differently and unpredictably to weight-loss medications.
Traditionally, for infections, antibiotics can give transient improvement, but often fail (for example, recurrent CDI), and these failures point-to a need for a fresh approach to treatment.
For transplantation, in many instances the infection cannot be demonstrated by culture as the diversity of microbial sub-species level composition is quite enormous, and only a small percentage of these can be cultured.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Devices, systems and methods for the production of humanized gut commensal microbiota
  • Devices, systems and methods for the production of humanized gut commensal microbiota
  • Devices, systems and methods for the production of humanized gut commensal microbiota

Examples

Experimental program
Comparison scheme
Effect test

example 1

n of Humanized Commensal Gut Microbiome for Various Treatments

[0156]Method

[0157]Microbiota from healthy human volunteers is collected by endoscopy (rectal or oral) and from fecal samples. Other methods such as samples left after surgical procedures can also be used to procure healthy microbiota and would be apparent for any person skilled in the art.

[0158]If the sample is a fecal sample, the donors are screened for the presence of ova and parasites in the stool culture. Specific pathogens to be screened for include, but are not limited to the following: Salmonella, Shigella, Escherichia coli, O157:H7, Yersinia enterocolitica; Campylobacter; Clostridium difficile toxins A and B; Cryptosporidium antigen and Giardia antigen.

[0159]If the sample is a serum sample, the sample is screened for pathogens includes but not limited to the following: HIV-1 and HIV-2; Hepatitis A, B, and C; rapid plasma regain; fluorescent treponemal antibody; and absorbed Treponema pallidum.

[0160]This step is n...

example 2

Species Diversity, Relative Proportion and Resistance Gene Profiling of the Commensal Flora

[0173]Humanized commensal microbiota with high diversity and proportion are produced from a seed culture, and can deliver metabolic benefits when administered to a host. The resistance genes of the microbiome are profiled for the presence of any resistance genes. Increased concentration of clostridial cluster XI and XVI is a feature of designer commensal flora. A typical designer commensal flora includes 500-1000 different species with below relative percentage proportions:

Bacteriodetes: 22-25%

Prevotella: 10%

Faecalibacterium: 5-8%

Eubacterium: 3-5%

Subdoligranulum: 0.5-1.0%

Roseburia: 0.25-0.5%

[0174]Further, the following typical pathogens presences are screened for exclusion:

Helicobacter pyroli

Acidovorax

[0175]Enterococcus faecalis

Genotoxic E coli

Genotoxic B. fragalis

Fusobacterium nucleatum

S. bovis

Salmonella

[0176]C. difficile

[0177]The human gut microbiota is dominated by five bacterial p...

example 3

for Ulcerative Colitis (UC) and Crohns Disease (CD) Using Commensal Microbiome Therapy

[0178]The commensal microbiota therapy for Crohns Disease and Ulcerative Colitis includes a highly diversified humanized commensal flora prepared from multiple donors and screened for species diversity and exclusion UC / CD-specific flora. The commensal flora is screened for resistome and other screening criteria as described in Example-1. The lyophilized commensal microbiota is delivered in two formats for the patients. Retention enema (500 mg commensal microbiome in 50 ml PBS) and as a capsule (500 mg capsule, one capsule / day). Patients were scheduled for a flexible sigmoidoscopy and also completed baseline questionnaires to obtain demographic information, Mayo score, and Inflammatory Bowel Disease questionnaire score.

[0179]Participants were given 50 mL commensal microbiome in PBS as a retention enema once per week for 8 weeks. The enema was administered with the patient in the left lateral positio...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

One embodiment provides a commensal gut production platform for ex vivo production of human gut commensal microbiota. Another embodiment provides devices, systems and methods for ex vivo culturing of gut microflora in a system that mimics the human gut environment. The culturing of the commensal microbiota in the disclosed systems produces gut microbiota having defined characteristics and properties that can be exploited to treat various conditions in a subject.

Description

FIELD OF THE INVENTION[0001]The present invention generally relates to the ex vivo production of gut microbiota and more particularly in a humanized commensal form that can be used for a variety of purposes such as therapeutics, diagnostics, and a research tool.BACKGROUND OF THE INVENTION[0002]The human microbiota is the aggregate of microorganisms that resides on the surface and in deep layers of skin, in the saliva and oral mucosa, in the conjunctiva, and in the gastrointestinal tracts, and the human microbiome refers to their genomes. The human body consisting of about 100 trillion cells and carries about ten times as many microorganisms in the intestines. It is estimated that these gut flora have around 100 times as many genes in aggregate as there are in the human genome. Indeed, by cell count, humans are 10% human and 90% bacterial flora. The microbiome is reckoned to have around 3 million functional genes compared to 23,000 genes in human beings. The far larger genome of the ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N1/20C12M1/00C12M1/34A61K9/00C12N1/04C12N7/00A61K35/74C12M1/12C12M3/00
CPCC12N1/20C12M25/10C12M23/20C12M41/14C12M41/34C12M23/42A61K2035/11C12N7/00A61K35/74A61K9/0031A61K9/0053C12N2795/00032C12N2795/00051C12N1/04C12M23/02C12M23/06C12M41/12C12N2795/00021Y02A50/30C12N1/205C12R2001/01C12R2001/19C12R2001/46C12R2001/145
Inventor SUBHADRA, BOBBAN
Owner SUBHADRA BOBBAN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products